Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library
Chitomur (bladder peptide complex): what the evidence says
At a glance
What it is: an oral capsule sold as a Khavinson bladder-tissue peptide complex. UNVERIFIED the product code (A-12), the source tissue and manufacturing method; these come from Nova's spec and seller descriptions.
What the evidence says: Human unlike the other complexes in this batch, two Russian-language randomized blind studies by the same group exist: one in women aged 48–80 with overactive bladder, R1 and one placebo-controlled study in men aged 62–83 with benign prostatic hyperplasia. R2 Both reported better urination measures and quality of life. UNVERIFIED sample sizes, doses and effect sizes; only short abstracts were available.
Biggest risks: none reported in either study, but the studies were small and short. UNVERIFIED safety data beyond the abstracts.
Rating
| Human Human evidence | Very limited: two small blind trials R1, R2 |
| Animal Animal / lab evidence | Not reviewed |
| Regulatory | Not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page R3, R4, R5 · not named by WADA R6 |
| Established human dose | No |
Evidence verdict: Overactive bladder (older women) and BPH urinary symptoms (older men): Very limited (two small Russian blind trials)
This page reports what studies used. It is not dosing advice.
Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source
About the evidence: both studies come from one research group, were published in a Russian gerontology journal, and give few numbers in the abstracts. They have not been replicated independently.
What is it?
Related pages: prostamax, libidon.
Does it work?
- Human Overactive bladder in women: fewer urgency and incontinence episodes. R1
- Human BPH in men: improved urination measures; benefit lasted a month after stopping. R2
Is it safe?
- Human No adverse effects reported in either study. R1, R2
Gray-market vials: extra risks
A gray-market vial has no quality control and no guarantee of identity, strength or sterility. We test retail vials blind under the Open Peptide Standard; see /tests/. A passing test covers one batch on one date and does not mean the compound is safe.
Is it legal?
- US: not FDA-approved; no Drugs@FDA application found (openFDA searched Oct 27, 2026).
- Compounding: not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page. R3, R4, R5
- Sport: not named on WADA's 2026 Prohibited List. R6
Study details
Study details
These are amounts researchers used, not recommendations.
| Study | People / model | Route | Amount used | Follow-up | Reported | Citation |
|---|---|---|---|---|---|---|
| Gomberg 2013a | Women 48–80, overactive bladder | Oral | Not stated in abstract | Per study | Symptoms improved | PMID 28976156 |
| Gomberg 2013b | Men 62–83, BPH | Oral | Not stated in abstract | Course + 1 month | Urination improved vs placebo | PMID 24640697 |
Full reference list (PubMed, CT.gov, FDA and WADA checked Oct 27, 2026)
- R1 Gomberg VG, et al. Adv Gerontol. 2013. PMID 28976156
- R2 Gomberg VG, et al. Adv Gerontol. 2013. PMID 24640697
- R3 FDA, 503A bulk drug substances categories list (updated May 14, 2026). https://www.fda.gov/media/94155/download
- R4 FDA, 503B bulk drug substances categories list (updated Mar 21, 2025). https://www.fda.gov/media/94164/download
- R5 FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current Apr 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- R6 WADA. The 2026 Prohibited List, full list checked; compound not named. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
Disclaimer
This page is for education and harm reduction, not medical advice or a recommendation to use Chitomur (bladder peptide complex). This compound is not FDA-approved. Any product sold under this name in the US is unregulated. Report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).